Show simple item record

dc.contributor.authorReekie, J.
dc.contributor.authorLevy, M.
dc.contributor.authorRichards, A.
dc.contributor.authorWake, C.
dc.contributor.authorSiddall, D.
dc.contributor.authorBeasley, H.
dc.contributor.authorKumar, S.
dc.contributor.authorButler, Tony
dc.identifier.citationReekie, J. and Levy, M. and Richards, A. and Wake, C. and Siddall, D. and Beasley, H. and Kumar, S. et al. 2014. Trends in prevalence of HIV infection, hepatitis B and hepatitis C among Australian prisoners - 2004, 2007, 2010. Medical Journal of Australia. 200 (5): pp. 277-280.

Objective: To report the prevalence of markers for HIV infection, hepatitis B and hepatitis C among Australian prison entrants. Design: Cross-sectional survey conducted over 2-week periods in 2004, 2007 and 2010. Setting: Reception prisons in New South Wales, Queensland, Tasmania and Western Australia. Participants: Individuals entering prison from the community during the survey periods. Main outcome measure: Prevalence of anti-HIV antibody (anti-HIV), hepatitis B surface antigen (HBsAg), anti-hepatitis B core antibody (anti-HBc) and anti-hepatitis C virus antibody (anti-HCV). Results: The study included 1742 prison entrants: 588 (33.8%) in 2004, 536 (30.8%) in 2007 and 618 (35.5%) in 2010. The age-standardised prevalence estimates for anti-HIV, HBsAg and anti-HBc were 0.4%, 2.3% and 21.7% respectively, and remained stable over the three survey periods. The age-standardised prevalence estimate for anti-HCV was 29.0%; it decreased over time (33.3% in 2004 v 23.2% in 2010; P = 0.001), and this coincided with a decrease in prison entrants reporting injecting drug use (58.3% [343/588] in 2004 v 45.3% [280/618] in 2010; P < 0.001). Among injecting drug users, the prevalence of anti-HCV was 57.2% and did not change significantly over time. Of those who were anti-HCV positive, 33.7% (140/415) were unaware of their infection status, and 74.3% (185/249) of those who tested positive for anti-HBc reported that they had never had hepatitis B. Conclusions: HIV prevalence is low in the Australian prisoner population but transmission remains a risk. Despite a decrease in the proportion of prison entrants reporting injecting drug use, prevalence of hepatitis B and hepatitis C has remained high. Treatment and prevention initiatives should be prioritised for this population.

dc.titleTrends in prevalence of HIV infection, hepatitis B and hepatitis C among Australian prisoners - 2004, 2007, 2010
dc.typeJournal Article
dcterms.source.titleMedical Journal of Australia
curtin.departmentNational Drug Research Institute (NDRI)
curtin.accessStatusFulltext not available

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record